{"id":198837,"date":"2024-11-05T23:10:35","date_gmt":"2024-11-06T05:10:35","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/11\/gene-therapy-improves-eye-health-and-reduces-the-need-for-anti-vegf-injections-in-age-related-macular-degeneration"},"modified":"2024-11-05T23:26:42","modified_gmt":"2024-11-06T05:26:42","slug":"gene-therapy-improves-eye-health-and-reduces-the-need-for-anti-vegf-injections-in-age-related-macular-degeneration","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/11\/gene-therapy-improves-eye-health-and-reduces-the-need-for-anti-vegf-injections-in-age-related-macular-degeneration","title":{"rendered":"Gene therapy Improves Eye Health and Reduces the Need for Anti-VEGF Injections in Age-Related Macular Degeneration"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/gene-therapy-improves-eye-health-and-reduces-the-need-for-anti-vegf-injections-in-age-related-macular-degeneration.jpg\"><\/a><\/p>\n<p><a href=\"https:\/\/www.regenxbio.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">RegenxBio<\/a>, a publicly-traded biotech firm, released data this week from a Phase 2 clinical trial designed to test its leading genetic therapy product in patients with bilateral wet age-related macular degeneration (AMD). AMD is characterized by abnormal growth of blood vessels in the retina, and is a leading cause of loss of vision in elderly populations globally.<\/p>\n<p>ABBV-RGX-314, developed in collaboration with AbbVie, offers the potential of a one-time treatment for wet AMD and other retinal conditions, including diabetic retinopathy. This is in contrast to existing treatments which rely on repeated intraocular injections of drugs that inhibit a protein known as Vascular Endothelial Growth Factor (VEGF), a protein responsible for the formation of new retinal blood vessels.<\/p>\n<p>The ABBV-RGX-314 therapy is based on a an AAV8 viral vector as a delivery system. The AAV8 platform has been genetically engineered to encode an antibody that can inhibit VEGF for the long-term.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>RegenxBio, a publicly-traded biotech firm, released data this week from a Phase 2 clinical trial designed to test its leading genetic therapy product in patients with bilateral wet age-related macular degeneration (AMD). AMD is characterized by abnormal growth of blood vessels in the retina, and is a leading cause of loss of vision in elderly [\u2026]<\/p>\n","protected":false},"author":726,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11,412,269],"tags":[],"class_list":["post-198837","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical","category-genetics","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/198837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/726"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=198837"}],"version-history":[{"count":1,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/198837\/revisions"}],"predecessor-version":[{"id":198841,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/198837\/revisions\/198841"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=198837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=198837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=198837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}